Omnilax (Macrogol 4000)

Macrogol 4000, the active ingredient in Omnilax, is an osmotic laxative presented as a powder for oral use. It works by retaining water in the intestinal lumen to soften stool and facilitate bowel movements, and is indicated for the treatment of constipation and for bowel cleansing before diagnostic procedures.

GNH USA supplies Omnilax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export globally.

Omnilax (macrogol 4000) is used as an osmotic laxative to manage conditions affecting bowel transit.

- Chronic constipation: softens stool and promotes regular bowel movements in patients with persistent constipation. - Occasional constipation: provides rapid relief of infrequent constipation episodes. - Bowel preparation: facilitates intestinal cleansing before colonoscopy or other diagnostic procedures.

Macrogol 4000 may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating: feeling of fullness or swelling in the abdomen. - Flatulence: increased intestinal gas. - Nausea: mild sensation of wanting to vomit. - Diarrhea: loose, watery stools. - Abdominal cramps: intermittent stomach pain. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Severe electrolyte imbalance: abnormal levels of sodium, potassium or other electrolytes. - Allergic reaction: rash, itching, swelling or difficulty breathing. - Severe abdominal pain: intense or persistent pain requiring medical attention. - Rectal bleeding: presence of blood in stool. - Dehydration: excessive fluid loss leading to dizziness or low blood pressure.

Before using Omnilax, certain precautions should be considered to ensure safe and effective use.

- Hydration status: assess and maintain adequate fluid intake during treatment. - Intestinal obstruction: avoid use in patients with known or suspected bowel blockage. - Renal impairment: use cautiously and monitor renal function in patients with kidney disease. - Electrolyte monitoring: consider periodic electrolyte checks during prolonged therapy. - Concomitant laxatives: limit use of other osmotic or stimulant laxatives to reduce risk of imbalance. - Store at room temperature: keep in the original container, protect from moisture and heat.

Macrogol 4000 can affect the absorption of several concomitant medications.

Major Interactions (Avoid): - Other osmotic laxatives: combined use may cause excessive fluid loss and electrolyte disturbances. - High‑dose mineral supplements: may reduce effectiveness of macrogol and alter mineral balance.

Moderate Interactions (Monitor Closely): - Antacids: may have reduced absorption when taken together. - Oral contraceptives: macrogol may decrease plasma levels, consider alternative contraception. - Digoxin: possible reduced absorption, monitor therapeutic levels. - Lithium: decreased lithium levels, monitor serum concentrations. - Warfarin: potential alteration of INR, monitor coagulation status.